Literature DB >> 22664073

Bacterial cell wall compounds as promising targets of antimicrobial agents II. Immunological and clinical aspects.

Tobias Schuerholz1, Sabine Dömming, Mathias Hornef, Aline Dupont, Ina Kowalski, Yani Kaconis, Lena Heinbockel, Jörg Andrä, Patrick Garidel, Thomas Gutsmann, Sunil David, Susana Sánchez-Gómez, Guillermo Martinez de Tejada, Klaus Brandenburg.   

Abstract

The bacterial cell wall represents the primary target for antimicrobial agents. Microbial destruction is accompanied by the release of potent immunostimulatory membrane constituents. Both Gram-positive and Gram-negative bacteria release a variety of lipoproteins and peptidoglycan fragments. Gram-positive bacteria additionally provide lipoteichoic acids, whereas Gram-negative bacteria also release lipopolysaccharide (LPS, endotoxin), essential component of the outer leaflet of the bacterial cell wall and one of the most potent immunostimulatory molecules known. Immune activation therefore can be considered as an adverse effect of antimicrobial destruction and killing during anti-infective treatment. In contrast to antibiotics, the use of cationic amphiphilic antimicrobial peptides allows both effective bacterial killing and inhibition of the immunostimulatory effect of the released bacterial membrane constituents. The administration of antimicrobial peptides alone or in combination with antibiotic agents thus represents a novel strategy in the antiinfective treatment with potentially important beneficial aspects. Here, data are presented which describe immunological and clinical aspects of the use of antimicrobial peptides (AMPs) as therapeutic agents to treat bacterial infection and neutralize the immunostimulatory activity of released cell wall constituents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664073     DOI: 10.2174/138945012802002438

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  3 in total

1.  Lipoproteins/peptides are sepsis-inducing toxins from bacteria that can be neutralized by synthetic anti-endotoxin peptides.

Authors:  Guillermo Martinez de Tejada; Lena Heinbockel; Raquel Ferrer-Espada; Holger Heine; Christian Alexander; Sergio Bárcena-Varela; Torsten Goldmann; Wilmar Correa; Karl-Heinz Wiesmüller; Nicolas Gisch; Susana Sánchez-Gómez; Satoshi Fukuoka; Tobias Schürholz; Thomas Gutsmann; Klaus Brandenburg
Journal:  Sci Rep       Date:  2015-09-22       Impact factor: 4.379

2.  Structural systems pharmacology: A framework for integrating metabolic network and structure-based virtual screening for drug discovery against bacteria.

Authors:  Elmira Nazarshodeh; Sayed-Amir Marashi; Sajjad Gharaghani
Journal:  PLoS One       Date:  2021-12-14       Impact factor: 3.240

3.  The anti-inflammatory effect of the synthetic antimicrobial peptide 19-2.5 in a murine sepsis model: a prospective randomized study.

Authors:  Tobias Schuerholz; Sabine Doemming; Mathias Hornef; Lukas Martin; Tim-Philipp Simon; Lena Heinbockel; Klaus Brandenburg; Gernot Marx
Journal:  Crit Care       Date:  2013-01-09       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.